Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
J Clin Exp Hematop. 2019;59(2):98-100
Authors: Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Nishikawa T
PMID: 31257351 [PubMed - in process]
Source: Journal of Clinical and Experimental Hematopathology : JCEH - Category: Hematology Tags: J Clin Exp Hematop Source Type: research